RESEARCH TRIANGLE PARK, N.C. – , a privately held RTP firm focused on blood-related and coagulation products, will receive up to $6 million from the U.S. Navy for further product development.

The company will use the funds for a dehydrated product (Stasix) to stop internal bleeding and a dehydrated form of human plasma (Resusix) for trauma patient infusion.

The Navy has been a longtime support of Entegrion’s research and development in its search for products to improve combat and traumatic injuries.

“Our military does a heroic job in overcoming the logistical challenges of ensuring that critically needed blood supplies are available when and where they are needed,” said Joseph DaCorta, Entegrion’s chief technology officer, in a statement. “Trends in clinical practice are moving toward earlier and more aggressive use of blood components after serious injury. However, availability of such therapies is often seriously restricted by shelf-life limitations and storage requirements.

“Technologies like ours to produce blood-derived products that can be stored for longer periods, do not require refrigeration, and have fewer pathogens will support both military and civilian medical operations by ensuring both the safety and timely availability of blood products to treat serious injuries, particularly in remote and austere areas,” he added.

Last November, Entegrion launched commercial sales of its proprietary bandages that are designed to promote blood clotting.

The company, which utilizes technology developed at the University of North Carolina at Chapel Hill and East Carolina University, recently received Food and Drug Administration approval for one of its bandages called Stasilon.

The bandages are sold by LC Industries, which is based in Durham.

Entegrion developed the technology in cooperation with the U.S. Office of Naval research.

The bandages come in 4-inch and 2-inch square sizes.